AN 238

Drug Profile

AN 238

Alternative Names: AN-238

Latest Information Update: 06 Oct 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AEterna Zentaris Inc
  • Class Anthracyclines; Antineoplastics; Pyrroles
  • Mechanism of Action DNA intercalators; Somatostatin receptor agonists; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 06 Oct 2008 Discontinued - Preclinical for Solid tumours in USA (IV)
  • 01 Jun 2006 This compound is still in active development
  • 30 Dec 2002 Zentaris has been acquired by AEterna Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top